Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...
Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...
TAMPA, Fla. — Ovarian cancer, often diagnosed at an advanced stage, presents significant treatment challenges because patients tend to develop resistance to conventional therapies quickly. Despite ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. It's really changed the way we think about ...
A simple new blood test developed by Victorian researchers can pinpoint which women with ovarian cancer will likely respond ...
New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular ...
Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
HONOLULU — A new analysis of the phase 3 NOVA trial strengthens earlier findings that niraparib (Zejula, Tesaro) provides meaningful clinical benefit for patients with platinum-sensitive, recurrent ...
Patient-reported experience with an immunotherapy telehealth platform. Aware of the use of PARP inhibitors in the treatment of Ovarian Cancer 29 (85.29) Not aware of the use of PARP Inhibitors in the ...
A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback